What is of a bigger concern is that sales of chronic therapies — usually more resilient — are also sluggish, with cardiac drugs even registering a decline of 4% month-on-month. The negative growth is attributed to the base effect, an industry expert said — the base of higher sales of Covid-related portfolio in the corresponding period of the previous year. Amid the Delta wave, sales of anti-respiratory, painkillers, antibiotics and anti-virals had spiralled.
Significantly, excluding Covid-related medication drugs, the market was flat in April, showing a negative growth of 0.5%, the latest figures by market research IQVIA firm said.
Overall, the pharma retail market was valued at Rs 1,44,486 crore with a 13% growth at MAT (moving annual total), or the 12-month period ended April. For the month alone, it was around Rs 13,502 crore.
Sluggish sales at this stage reaffirm fears of an impact on earnings, with the industry already facing headwinds from rising input, logistics costs, and shutdowns and supply disruptions from China over the last few months.
The market registered tepid sales among most therapies, excluding Covid-related medicines, during most of 2020 due to the absence of prescriptions and lower OPD (outpatient department) visits. In 2021, the market slowly bounced back with lockdowns and restrictions removed across the country.
